The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Modular microfluidic platform for mimicking multi-organ system interactions. This project aims to develop a novel, modular microfluidic platform that overcomes current limitations of integrated systems in synchronising multi-tissue culture, imaging and operational complexity. Understanding multi-organ systemic crosstalk in human health and diseases demands dynamic culture systems that can mimic such interactions. This project will deliver a first-in-class platform technology and establish intern ....Modular microfluidic platform for mimicking multi-organ system interactions. This project aims to develop a novel, modular microfluidic platform that overcomes current limitations of integrated systems in synchronising multi-tissue culture, imaging and operational complexity. Understanding multi-organ systemic crosstalk in human health and diseases demands dynamic culture systems that can mimic such interactions. This project will deliver a first-in-class platform technology and establish international and disciplinary collaborations to develop different tissue and engineering modules relevant to applications in systemic nanotoxicology, drug bioactivation and chronic diseases. This will provide the cornerstone technology to develop a new generation of disease models and therapeutics targeting interaction dysfunctions.Read moreRead less